文档介绍：临床医学论文-倍他乐克治疗慢性顽固性充血性心力衰竭的临床分析
【摘要】  目的:观察β-受体阻滞剂倍他乐克治疗慢性顽固性充血性心力衰竭(CHF)的临床疗效及安全性。方法:将57例病因不同的患者随机分为两组,对照组按常规抗心力衰竭治疗,包括休息、低盐饮食、吸氧、应用血管紧张素转换酶抑制剂(ACEI)、洋地黄、利尿剂、抗心律失常、消除心力衰竭诱因等综合措施。治疗组在对照组的基础上给予倍他乐克,,如无特殊,逐渐加量直到靶剂量50mg/d或最大的耐受量(最大耐受量是指患者在加量后心功能无恶化,收缩压不低于90mmHg,静息时心率不低于55次/min,活动时心率不低于60次/min),观察16周。结果:%,%,%;%,%,%。两组比较差异有显著性(P<)。结论:β-受体阻滞剂倍他乐克治疗慢性顽固性充血性心力衰竭的疗效好,可明显改善心功能和临床症状,提高病人生活质量。
【关键词】  倍他乐克心力衰竭 NYHA心功能分级
Clinical Analysis of Betaloc on chronic obstinate Congestive Heart Failure
Abstract: Objective: To observe the effect and safety of beta-blocking agents betaloc in treating chronic obstinate CHF. Method: 57 cases were assigned with control group and treatment group randomly. The conventional treatment of CHF were adopted in control group that is rest, low salt diet, oxygen inhalation, and using ACEI, digitalis, diuretic, etc. The treatment group were added betaloc on the basic therapy of control group, the start dosage was mg/d and then to the target dosage of 50mg/d for the tolerance dosage, observed the effect for 16 weeks. Result: The rate of obvious effect effective, total effective was %, %, %, % and %, % in treatment group and control group respectively. There's significant difference between (P<). Conclusion: It's effective to treat chronic obstinate CHF with beta-b